BioMarin Pharmaceutical vs Repligen
BioMarin Pharmaceutical (BMRN), health care, and Repligen (RGEN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
BioMarin Pharmaceutical is worth $11.3B on the stock market and Repligen $10.4B: BioMarin Pharmaceutical is valued at 9% more. BioMarin Pharmaceutical's operating margin in its latest fiscal year was 12.7% and Repligen's 7.47%. Over the past year BioMarin Pharmaceutical's share price has moved +7.07% and Repligen's +6.35%.
Key facts
- BioMarin Pharmaceutical market value
- $11.3B
- Repligen market value
- $10.4B
- BioMarin Pharmaceutical revenue
- $3.2BFY to 2025-12-31
- Repligen revenue
- $738.3MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | BioMarin Pharmaceutical | Repligen |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $11.3Bhigher | $10.4Blower |
| Revenue | $3.2Bhigher | $738.3Mlower |
| Earnings | $348.9Mhigher | $48.9Mlower |
| Employees | 3,221higher | 2,000lower |
| Total assets | $7.6Bhigher | $2.9Blower |
| Valuation | ||
| P/E | — | — |
| P/S | 3.5lower | 14.0higher |
| P/B | 1.8lower | 4.4higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 12.7%higher | 7.47%lower |
| Balance sheet | ||
| Net assets | $6.1Bhigher | $2.1Blower |
| Total liabilities | $1.5Bhigher | $843.6Mlower |
| Total debt | — | $542.2M |
| Cash on hand | $1.3Bhigher | $566Mlower |
| Price change | ||
| Today | +0.90%higher | -0.37%lower |
| 1 year | +7.07%higher | +6.35%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
BioMarin Pharmaceutical only (3)
- Andreas Halvorsen1.2%
- Primecap team0.6%
- Dodge & Cox team0.5%
Repligen only (6)
- Lee Ainslie2.4%
- Wallace Weitz0.5%
- Brandon Haley0.4%
- Chuck Royce (founder)0.3%
- Stanley Druckenmiller0.2%
- Ron Baron0.2%
Percentages are each holding's share of that investor's reported portfolio. Who owns BMRN · Who owns RGEN
More on BioMarin Pharmaceutical
Further comparisons
BioMarin Pharmaceutical against its closest peers
Repligen against its closest peers
Learn
Questions and answers
Which is bigger, BioMarin Pharmaceutical or Repligen?
By market value, BioMarin Pharmaceutical is the larger: $11.3B against $10.4B for Repligen. By revenue in its latest fiscal year, BioMarin Pharmaceutical is the larger: $3.2B against $738.3M for Repligen.
Which has the higher operating margin?
BioMarin Pharmaceutical: 12.7%, against 7.47% for Repligen. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both BioMarin Pharmaceutical and Repligen?
None of the tracked superinvestors holds both in their latest 13F filing. 3 hold BioMarin Pharmaceutical and 6 hold Repligen.
Cite this page
Funkfolio, “BioMarin Pharmaceutical vs Repligen”, data as of 18 November 2026. https://funkfolio.com/compare/bmrn-vs-rgen
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.